Key statistics
On Monday, Fractyl Health Inc (GUTS:NMQ) closed at 2.54, 45.98% above the 52 week low of 1.74 set on Aug 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.82 |
---|---|
High | 2.83 |
Low | 2.50 |
Bid | 1.02 |
Offer | 3.84 |
Previous close | 2.79 |
Average volume | 557.56k |
---|---|
Shares outstanding | 47.93m |
Free float | 45.81m |
P/E (TTM) | -- |
Market cap | 121.74m USD |
EPS (TTM) | -1.37 USD |
Data delayed at least 15 minutes, as of Sep 23 2024 21:00 BST.
More ▼
Announcements
- Fractyl Health to Participate in Upcoming September Investor Conferences
- Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates
- Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita® Endoscopic Procedure
- Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024
- Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs
- Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day
- Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
- Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President’s Select Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions
- Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions
- Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
More ▼